One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic scents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials

JdR, Jr Costa; A Abizaid; AL Bartorelli; R Whitbourn; N Jepson; M Perin; C Steinwender; M Stuteville; D Ediebah; K Sudhir; PWJC (Patrick) Serruys

doi:10.4244/eijv12i10a206

One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic scents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials

JdR, Jr Costa, A Abizaid, AL Bartorelli, R Whitbourn, N Jepson, M Perin, C Steinwender, M Stuteville, D Ediebah, K Sudhir, PWJC (Patrick) Serruys

Cardiology

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1255-1262
Number of pages	8
Journal	EuroIntervention
Volume	12
Issue number	10
DOIs	https://doi.org/10.4244/eijv12i10a206
Publication status	Published - 2016

Research programs

EMC COEUR-09

Access to Document

10.4244/eijv12i10a206

Cite this

Costa, J. J., Abizaid, A., Bartorelli, AL., Whitbourn, R., Jepson, N., Perin, M., Steinwender, C., Stuteville, M., Ediebah, D., Sudhir, K., & Serruys, PWJC. (2016). One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic scents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. EuroIntervention, 12(10), 1255-1262. https://doi.org/10.4244/eijv12i10a206

@article{53220b597c06485ab8ebe81340e7a1f1,

title = "One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic scents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials",

author = "Costa, {JdR, Jr} and A Abizaid and AL Bartorelli and R Whitbourn and N Jepson and M Perin and C Steinwender and M Stuteville and D Ediebah and K Sudhir and Serruys, {PWJC (Patrick)}",

year = "2016",

doi = "10.4244/eijv12i10a206",

language = "Undefined/Unknown",

volume = "12",

pages = "1255--1262",

journal = "EuroIntervention",

issn = "1774-024X",

publisher = "Europa Group",

number = "10",

}

Costa, JJ, Abizaid, A, Bartorelli, AL, Whitbourn, R, Jepson, N, Perin, M, Steinwender, C, Stuteville, M, Ediebah, D, Sudhir, K & Serruys, PWJC 2016, 'One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic scents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials', EuroIntervention, vol. 12, no. 10, pp. 1255-1262. https://doi.org/10.4244/eijv12i10a206

One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic scents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. / Costa, JdR, Jr; Abizaid, A; Bartorelli, AL et al.
In: EuroIntervention, Vol. 12, No. 10, 2016, p. 1255-1262.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic scents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials

AU - Costa, JdR, Jr

AU - Abizaid, A

AU - Bartorelli, AL

AU - Whitbourn, R

AU - Jepson, N

AU - Perin, M

AU - Steinwender, C

AU - Stuteville, M

AU - Ediebah, D

AU - Sudhir, K

AU - Serruys, PWJC (Patrick)

PY - 2016

Y1 - 2016

U2 - 10.4244/eijv12i10a206

DO - 10.4244/eijv12i10a206

M3 - Article

SN - 1774-024X

VL - 12

SP - 1255

EP - 1262

JO - EuroIntervention

JF - EuroIntervention

IS - 10

ER -

Costa JJ, Abizaid A, Bartorelli AL, Whitbourn R, Jepson N, Perin M et al. One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic scents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. EuroIntervention. 2016;12(10):1255-1262. doi: 10.4244/eijv12i10a206